We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

This study has been terminated.
(Closed per Data Monitoring Committee due to toxicity & incomplete treatment of patients resulting in poor data.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00290706
First Posted: February 13, 2006
Last Update Posted: August 12, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Eli Lilly and Company
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Northwestern University
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: March 2019
  Estimated Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)